Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference

Core Insights - Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing novel radioimmunotherapy and antibody-based therapeutic products for cancer treatment [3] Group 1: Company Overview - The company is known for its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and bispecific antibodies generated using the Y-BiClone platform [3] - Y-mAbs has a broad and advanced product pipeline, including DANYELZA® (naxitamab-gqgk), which is the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after prior therapy [3] Group 2: Upcoming Events - Michael Rossi, President and CEO of Y-mAbs, will participate in a fireside chat at the Oppenheimer 35th Annual Life Sciences Conference on February 11, 2025, at 4:40 p.m. ET [1] - A live webcast of the event will be available on the company's investor relations website and will be archived for 30 days after the event [2]